229 related articles for article (PubMed ID: 35347870)
1. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Du X; Bai H; Wang Z; Daun J; Liu Z; Xu J; Chang G; Zhu Y; Wang J
Thorac Cancer; 2022 May; 13(9):1289-1298. PubMed ID: 35347870
[TBL] [Abstract][Full Text] [Related]
2. Development, internal validation and calibration of a risk score to predict survival in patients with
Ng IK; Kumarakulasinghe NB; Syn NL; Soo RA
J Clin Pathol; 2021 Feb; 74(2):116-122. PubMed ID: 32576630
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
4. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
5. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
[TBL] [Abstract][Full Text] [Related]
6. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
[TBL] [Abstract][Full Text] [Related]
7. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
8. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
[TBL] [Abstract][Full Text] [Related]
9. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand.
Aye PS; Tin Tin S; McKeage MJ; Khwaounjoo P; Cavadino A; Elwood JM
BMC Cancer; 2020 Jul; 20(1):658. PubMed ID: 32664868
[TBL] [Abstract][Full Text] [Related]
14. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of skeletal muscle measured by CT at the T4 level in advanced EGFR-positive non-small cell lung cancer patients treated with ecotinib].
Xia H; Tan XY; Lu XT; Wang SF; Cao YQ; Luo P; Song SW; Guo MF; Yang L; Jin Y
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1590-1600. PubMed ID: 38742346
[No Abstract] [Full Text] [Related]
16. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Ferrara MG; Martini M; D'Argento E; Forcella C; Vita E; Di Noia V; Sperduti I; Bilotta M; Ribelli M; Damiano P; Cannella A; Stefani A; Pilotto S; Carbone C; Piro G; Milella M; Tortora G; Bria E
Clin Lung Cancer; 2021 Jul; 22(4):351-360. PubMed ID: 33558194
[TBL] [Abstract][Full Text] [Related]
17. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
[TBL] [Abstract][Full Text] [Related]
18. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
19. A predictive model based on liquid biopsy for non-small cell lung cancer to assess patient's prognosis: Development and application.
Gu T; Ren J; Hu Z; Wei Y; Huang J
Tissue Cell; 2022 Aug; 77():101854. PubMed ID: 35752028
[TBL] [Abstract][Full Text] [Related]
20. [Results of EGFR Mutations Detected in Pleural Effusion and Its
Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer:
A Retrospective Study in A Single Center].
Lu T; Li Q; Li L; Yang K; Zhou D; Gao J; Chen M; Xu Y; Zhong W; Wang M; Liang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1059-1065. PubMed ID: 33357312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
